This article is more than 5 years old. Information may no longer be current.

Vistakon introduces topical solution for corneal ulcers

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

JACKSONVILLE, Fla. — Vistakon Pharmaceuticals has introduced a new topical ocular anti-infective solution called IQUIX, the company announced in a press release. The solution contains 1.5% levofloxacin and is currently the only newer-generation fluoroquinolone approved by the U.S. Food and Drug Administration for treating corneal ulcers, according to the release.

The IQUIX formulation rapidly penetrates corneal tissue and provides broad coverage of gram-negative and gram-positive pathogens, including Corynebacterium species, Staphylococcus aureus, Staphylococcus epidermis, Streptococcus pneumoniae, Viridans group streptococci, Pseudomonas aeruginosa and Serratia marcescens. The solution eradicates these pathogens by inhibiting both topoisomerase 4 and DNA gyrase, according to the release.

IQUIX is preservative free and was well-tolerated in clinical trials. Additionally, when tested in human cell cultures, levofloxacin demonstrated less cytotoxicity than other marketed fluoroquinolones, the release said.